Juvenile ankylosing spondylitis.

Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI)

Background: Increased incidence of renal stone has been reported in ankylosing spondylitis (AS), but unlike some well-known renal involvements, they have not been fully studied. The aim of this study was to investigate the association of AS with urolithiasis and also the relation between urinary stone and severity markers. Methods: One hundred-sixty three AS patients were included in a cross-s...

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis

Background Juvenile onset sondylarthropathy is a term that refers to a group of human leucocyte antigen (HLA) -B27 associated inflammatory disorders affecting children under the age of 16 years. The increased expression of tumor necrosis factor alpha (TNF-alpha) in synovial tissue of patients with juvenile onset and adults with active ankylosing spondylitis suggests a significant pathogenic rol...

DMARD in rheumatoid a rthritis and psoriatic arthrits. The proportions of patients who have re - ceived anti-TNF drugs in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis

Intra-rater reliability of the bath ankylosing spondylitis disease activity index (BASDAI) and the bath ankylosing spondylitis functional index (BASFI) in children with spondyloarthritis

Purpose Juvenile spondyloarthritis (JSpA), referred to as enthesitisrelated arthritis (ERA) sub-type under the International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis (JIA), is characterized by inflammation in the joints and entheses. Axial involvement is uncommon at presentation but may develop in the second decade of life. Several instrumen...

Challenges in the management and research of juvenile-onset ankylosing spondylitis

615 ISSN 1758-4272 10.2217/IJR.13.60 © 2013 Future Medicine Ltd Int. J. Clin. Rheumatol. (2013) 8(6), 615–617 “...being able to stratify patients according to likely prognosis allows for tailored therapeutic decisions and being better able to balance the benefits of therapy with the potential side effects and economic costs.” Challenges in the management and research of juvenile-onset ankylosin...